Hussman Strategic Advisors Inc. Acquires Shares of 42,000 Immunocore Holdings PLC Sponsored ADR $IMCR

Hussman Strategic Advisors Inc. acquired a new stake in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 42,000 shares of the company’s stock, valued at approximately $1,458,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IMCR. State of New Jersey Common Pension Fund D grew its stake in Immunocore by 6.9% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 27,663 shares of the company’s stock valued at $960,000 after acquiring an additional 1,777 shares in the last quarter. R Squared Ltd raised its holdings in Immunocore by 7.4% in the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock valued at $307,000 after acquiring an additional 606 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in Immunocore by 115.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,109 shares of the company’s stock valued at $524,000 after acquiring an additional 8,088 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Immunocore by 37.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock valued at $74,000 after acquiring an additional 572 shares during the last quarter. Finally, Armistice Capital LLC raised its holdings in Immunocore by 21.5% in the 3rd quarter. Armistice Capital LLC now owns 824,000 shares of the company’s stock valued at $29,936,000 after acquiring an additional 146,000 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Immunocore Price Performance

Shares of IMCR stock opened at $28.16 on Monday. The firm’s 50-day moving average is $31.05 and its two-hundred day moving average is $33.40. The company has a market capitalization of $1.43 billion, a PE ratio of -40.23 and a beta of 0.74. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $27.44 and a 12 month high of $40.71. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.04 and a quick ratio of 4.01.

Immunocore (NASDAQ:IMCR) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.60) earnings per share (EPS) for the quarter. The company had revenue of $104.48 million during the quarter. Immunocore had a negative net margin of 8.88% and a negative return on equity of 9.20%. Analysts predict that Immunocore Holdings PLC Sponsored ADR will post -0.97 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have commented on IMCR shares. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. UBS Group set a $55.00 target price on Immunocore and gave the company a “buy” rating in a report on Wednesday, January 7th. Mizuho set a $38.00 target price on Immunocore in a report on Thursday, February 19th. Zacks Research lowered Immunocore from a “hold” rating to a “strong sell” rating in a report on Monday, April 27th. Finally, Jefferies Financial Group lowered Immunocore from a “buy” rating to a “hold” rating and reduced their price target for the stock from $48.00 to $33.00 in a report on Monday, March 16th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $60.89.

Insider Activity

In other news, CEO Bahija Jallal sold 11,474 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the sale, the chief executive officer directly owned 12,343 shares of the company’s stock, valued at approximately $399,296.05. The trade was a 48.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider David M. Berman sold 5,965 shares of the business’s stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total transaction of $192,967.75. Following the completion of the sale, the insider directly owned 5,859 shares in the company, valued at $189,538.65. This trade represents a 50.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 19,137 shares of company stock valued at $619,082. Company insiders own 10.40% of the company’s stock.

Immunocore Profile

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.